Clinical Trials Logo

Cutaneous Neurofibroma clinical trials

View clinical trials related to Cutaneous Neurofibroma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03105258 Not yet recruiting - Clinical trials for Neurofibromatosis Type 1

Selumetinib Pilot Study for Cutaneous Neurofibromas

Start date: May 1, 2017
Phase: Phase 2
Study type: Interventional

This is a small study of the oral MEK1/2 inhibitor, selumetinib, to evaluate the potential utility of selumetinib in individuals ≥ 18 years old with Neurofibromatosis 1 (NF1) and cutaneous neurofibromas (cNFs). The study aims to determine whether selumetinib will result in shrinkage of existing cutaneous neurofibromas and if it prevents or delays the development of new cutaneous neurofibromas.